Pomerantz LLP is investigating potential securities fraud claims against Ionis Pharmaceuticals following the failure of its Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy developed with AstraZeneca. The trial did not meet its primary endpoint, leading to a 23.9% drop in Ionis's stock price on July 9, 2026. The investigation targets whether Ionis and its executives engaged in unlawful business practices. Investors affected by the stock decline are advised to contact the law firm for possible class action participation.
Credo Technology Group reported a strong Q1 FY2027 with revenue up 114.7% year-on-year and solid non-GAAP profits, driven by its expanding AI connectivity portfolio and the DustPhotonics acquisition. Despite positive growth and a promising AI infrast...
PetroChina reported a 22% year-over-year increase in net income for the first half of 2026, driven by strong performance in its upstream and natural gas segments due to higher oil prices and cost optimization. The company expects continued profit gro...
The iShares Copper and Metals Mining ETF (ICOP) is rated a Buy amid copper's ongoing multidecade bull market, driven by strong technical and fundamental factors. In 2026, ICOP outperformed copper futures with a 29.3% gain year-to-date, compared to co...
Bitcoin is trading near $77,000-$79,000 amid rising Japanese government bond yields and a strong yen rally. Japan's 10-year bond yield reached 3% for the first time since 1996, pushing borrowing costs higher and triggering concerns over a $500 billio...
Concerns about circular financing in the AI sector are exaggerated, as such practices are common and serve as risk mitigation in mature industries. The AI industry's higher scrutiny is due to its immaturity and concentrated risks, not the novelty of ...
